AMLX — Amylyx Pharmaceuticals Share Price
Last trade - 00:00- $178.38m
- -$131.44m
- $380.79m
- 19
- 62
- 11
- 21
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.68 | ||
| Price to Tang. Book | 0.68 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.6 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -67.83% | ||
| Return on Equity | -51.22% | ||
| Operating Margin | -59.5% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 1.43 | 0.65 | 0.28 | 22.23 | 380.79 | 87.61 | 218.58 | 304.24% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Amylyx Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in the discovery and development of treatments for neurodegenerative diseases. The Company is focused on the development and commercialization of its product candidate: AMX0035 for the treatment of Wolfram syndrome and for the treatment of progressive supranuclear palsy, and AMX0114, the Company’s antisense oligonucleotide targeting calpain-2 for the treatment of amyotrophic lateral sclerosis (ALS). AMX0035 is a dual-unfolded protein response (UPR)-Bax apoptosis inhibitor composed of PB and TURSO (also known as TUDCA). The Company’s Avexitide is an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist that has been evaluated in five clinical trials for post-bariatric hypoglycemia (PBH) and has also been studied in congenital hyperinsulinism (HI), two indications characterized by hyperinsulinemic hypoglycemia.
Directors
- Last Annual
- December 31st, 2023
- Last Interim
- June 30th, 2024
- Incorporated
- January 10th, 2014
- Public Since
- January 7th, 2022
- No. of Shareholders
- 21
- No. of Employees
- 384
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 68,082,468
- Address
- 43 THORNDIKE STREET, CAMBRIDGE, 02141
- Web
- https://www.amylyx.com/
- Phone
- +1 6176820917
- Contact
- Lindsey Allen
- Auditors
- Deloitte & Touche LLP
Upcoming Events for AMLX
Similar to AMLX
Amgen
NASDAQ Global Select Market
Amneal Pharmaceuticals
NASDAQ Global Select Market
Amphastar Pharmaceuticals
NASDAQ Global Select Market
Apellis Pharmaceuticals
NASDAQ Global Select Market
AstraZeneca
NASDAQ Global Select Market
FAQ
As of Today at 19:43 UTC, shares in Amylyx Pharmaceuticals are trading at $2.62. This share price information is delayed by 15 minutes.
Shares in Amylyx Pharmaceuticals last closed at $2.62 and the price had moved by -86.64% over the past 365 days. In terms of relative price strength the Amylyx Pharmaceuticals share price has underperformed the S&P500 Index by -89.43% over the past year.
The overall consensus recommendation for Amylyx Pharmaceuticals is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreAmylyx Pharmaceuticals does not currently pay a dividend.
Amylyx Pharmaceuticals does not currently pay a dividend.
Amylyx Pharmaceuticals does not currently pay a dividend.
To buy shares in Amylyx Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $2.62, shares in Amylyx Pharmaceuticals had a market capitalisation of $178.38m.
Here are the trading details for Amylyx Pharmaceuticals:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: AMLX
Based on an overall assessment of its quality, value and momentum Amylyx Pharmaceuticals is currently classified as a Value Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Amylyx Pharmaceuticals is $4.25. That is 62.21% above the last closing price of $2.62.
Analysts covering Amylyx Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of -$4.13 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Amylyx Pharmaceuticals. Over the past six months, its share price has underperformed the S&P500 Index by -25.99%.
As of the last closing price of $2.62, shares in Amylyx Pharmaceuticals were trading -61.46% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Amylyx Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $2.62.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Amylyx Pharmaceuticals' directors